You are here: Industry Insights > BBT-401

News List

Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China prnasia
October 20, 2021
Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology, announced that the first subject has been dosed in the China Phase I clinical trial of BBT-401...
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis prnasia
June 15, 2021
Bridge Biotherapeutics (KQ288330) announced the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293).
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site prnasia
June 02, 2021
Bridge Biotherapeutics today announced the first patient dosing of BBT-401 in its open label, proof of mechanism study to examine the drug's efficacy and safety in active ulcerative colitis when delivered rectally to the colon (NCT04478825).
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC prnasia
January 05, 2020
Bridge Biotherapeutics plans to initiate a Phase I study of BBT-401 in Chinese subjects in May 2020. The safety, tolerability and pharmacokinetic data of the drug candidate will be assessed with single and multiple ascending oral doses in the study.